Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from Chardan Capital

Key Points

• Monopar Therapeutics has been given a "buy" rating by Chardan Capital, with a target price of $60.00, indicating a potential upside of 79.05% from its previous close.
• Recent trading saw Monopar's stock drop 6.7% on Wednesday, closing at $33.51, with a 52-week high of $54.30.
• Insiders have recently sold a total of 42,504 shares of Monopar Therapeutics, with significant decreases in their ownership percentages reported following these sales.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report)'s stock had its "buy" rating restated by stock analysts at Chardan Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have a $60.00 target price on the stock. Chardan Capital's price objective suggests a potential upside of 79.05% from the stock's previous close.

Several other equities analysts have also commented on MNPR. Cantor Fitzgerald assumed coverage on Monopar Therapeutics in a research note on Monday, July 7th. They issued an "overweight" rating and a $74.00 price target on the stock. Wall Street Zen raised Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $60.00.

Monopar Therapeutics Trading Down 6.7%

NASDAQ MNPR traded down $2.39 on Wednesday, reaching $33.51. 26,830 shares of the company were exchanged, compared to its average volume of 39,824. The business's fifty day moving average price is $38.13 and its 200 day moving average price is $37.89. The stock has a market capitalization of $204.91 million, a P/E ratio of -9.63 and a beta of 1.05. Monopar Therapeutics has a fifty-two week low of $2.15 and a fifty-two week high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.12. Equities research analysts forecast that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Kim R. Tsuchimoto sold 8,904 shares of the company's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $356,160.00. Following the completion of the sale, the director directly owned 11,486 shares of the company's stock, valued at $459,440. This represents a 43.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher M. Starr sold 16,800 shares of the company's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the sale, the director directly owned 5,173 shares of the company's stock, valued at approximately $206,920. This trade represents a 76.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,504 shares of company stock worth $1,700,160 in the last quarter. 20.50% of the stock is owned by company insiders.

Institutional Trading of Monopar Therapeutics

A number of hedge funds have recently added to or reduced their stakes in MNPR. Police & Firemen s Retirement System of New Jersey acquired a new stake in Monopar Therapeutics during the 2nd quarter worth approximately $34,000. AlphaQuest LLC purchased a new position in shares of Monopar Therapeutics during the 1st quarter worth approximately $44,000. JPMorgan Chase & Co. purchased a new position in shares of Monopar Therapeutics during the 4th quarter worth approximately $45,000. New York State Common Retirement Fund purchased a new position in shares of Monopar Therapeutics during the 2nd quarter worth approximately $104,000. Finally, Gerber LLC purchased a new position in shares of Monopar Therapeutics during the 1st quarter worth approximately $204,000. 1.83% of the stock is owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.